Novartis Reference: PAT051937-US-PCT

Mofo Reference: 223002100300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Examiner: B. J. Gangle

Mariagrazia PIZZA

Application No.: 10/530,753

Filing Date: (Intl.) October 2, 2003

For: POLYPEPTIDE-VACCINES FOR

BROAD PROTECTION AGAINST HYPERVIRULENT MENINGOCOCCAL.

LINEAGES

Group Art Unit: 1645

Confirmation No.: 7340

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & § 1.98

MAIL STOP: AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98. Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

Application No.: 10/530,753 2 Novartis Reference: PAT051937-US-PCT
Mofo Reference: 223002100300

	This Su	applemental Information Disclosure Statement is submitted:	
	With	the application; accordingly, no fee or separate requirements are required.	
\boxtimes	Befor	efore the mailing of a first Office Action after the filing of a Request for Continued	
	Exan	nination under 37 C.F.R. § 1.114. However, if applicable, a certification under 37	
	C.F.I	.F.R. § 1.97 (e)(1) has been provided.	
	Withi	Within three months of the application filing date or before mailing of a first Office Action	
	on the	on the merits; accordingly, no fee or separate requirements are required. However, if	
	applio	cable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.	
	After receipt of a first Office Action on the merits but before mailing of a final		
	or No	or Notice of Allowance.	
		A fee is required. Accordingly, a Fee Transmittal Form (PTO/SB/17) is attached to	
		this submission.	
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is	
		believed to be due.	
	After	After mailing of a final Office Action or Notice of Allowance, but before payment of the	
	Issue	Issue Fee.	
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal	
		Form (PTO/SB/17) is attached to this submission.)	

Applicants would appreciate the Examiner initialing and returning the Form PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Application No.: 10/530,753 3 Novartis Reference: PAT051937-US-PCT Mofo Reference: 223002100300

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing Docket No. 223002100300.

Dated: September 24, 2010 Respectfully submitted,

By /Otis Littlefield/
Otis B. Littlefield
Registration No.: 48.751

MORRISON & FOERSTER LLP 425 Market Street San Francisco, California 94105-2482 Telephone: 415.268.6846 Fax: 415.268.7522